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Klara Tenner-Racz*, Christiane Stahl Hennig†, Klaus Überla‡, Heribert Stoiber§, Ralf Ignatius¶, Jonathan Heeney,
Ralph M. Steinman**††, and Paul Racz*
*Department of Pathology and Koerber Laboratory for AIDS Research, Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany;
†Deutsches Primatenzentrum, Kellnerweg 4, 37077 Göttingen, Germany; ‡Department of Molecular and Medical Virology, Ruhr University Bochum,
Universitaetstrasse 150, 44780 Bochum, Germany; §Institute of Hygiene and Social Medicine, Fritz-Preglstrasse 3, A-6020 Innsbruck, Austria;
¶Department of Medical Microbiology and Infection Immunology, Free University Berlin, Hindeburgdamm 27, 12203 Berlin, Germany;
Department of Virology, Biomedical Primate Research Center, 151 Lange Kleiwig, 2288 GJ Rijswijk, The Netherlands; and **Laboratory of
Cellular Physiology and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021-6399
Contributed by Ralph M. Steinman, December 30, 2003
Atraumatic application of attenuated SIVmac239nef vaccine to
the tonsils of rhesus macaques provided protection against chal-
lenge 26 weeks later with infectious SIVmac251 applied through
this route. Early events at the mucosal portal of entry of challenge
virus were followed. Wild-type virus was detected in nonvacci-
nated controls by day 4, and then simian immunodeficiency virus
(SIV) replicated vigorously at days 7 and 14. In contrast, a challenge
of 10 of 10 vaccinees with SIV did not significantly raise RNA levels
in the plasma or increase infected cells in lymphoid tissues, as
assessed by single-cell labeling for viral RNA and nef protein.
Vaccine virus was found in the tonsils of all vaccinees, but chal-
lenge virus was only detected at this portal of entry in 4 of 10
monkeys. In the tonsil, the challenge virus did not induce an
expansion of perforin killer cells. However, there was a significant
increase in  T cells and mature dendritic cells relative to unvac-
cinated controls. Therefore, during tonsillar SIVnef vaccination,
infection is blocked early at the entry portal, which we propose is
due in part to innate functions of  T and dendritic cells.
S imian immunodeficiency virus (SIV) infection of rhesusmacaques provides a model for HIV infection in humans. It
would be valuable to determine whether vaccination against SIV
blocks infection at the site of viral entry, including mucosal
surfaces. Most efforts have instead been directed to the long-
term effects of the vaccine. Also, the extent of protection is
generally monitored in blood, and more information is needed
on protection in lymphoid tissues, where the virus replicates and
immune responses are generated. We have considered these
questions by analyzing early changes in rhesus macaques immu-
nized with a live attenuated SIV vaccine, generated by deletion
of the nef gene, and challenged with wild-type SIV through the
tonsils. We realized that early events during the entry of a
vaccine and challenge virus were readily amenable to analysis in
tonsils, which are a model for transmission through mucosa-
associated lymphoid tissue (MALT), e.g., in anal transmission by
means of rectal MALT.
MALT is comprised of a lymphoepithelium equipped with
antigen transporting M cells that allows infectious agents and
vaccines to access lymphoid tissue lying beneath it. Each region
of the MALT contributes to the pathogenesis of infections and
protective vaccines (1). MALT provides sites for the replication
of immunodeficiency viruses in vivo, both HIV in humans (2, 3)
and SIV in monkeys (4). Beneath the epithelium are dendritic
cells (DCs) (3, 5). In tissue culture, DCs transmit HIV (6–8) and
SIV (9) for replication in T cells. DCs also present HIV (10–12)
and SIV (13) antigens to specific T cells.
We have previously followed infectious (14) and vaccine (15)
forms of SIV following their atraumatic application to lingual
and palatine tonsils. The virus begins to replicate in oral MALT,
primarily in T cells, and then spreads to distal lymphoid organs.
Here, we use the accessibility of the oral MALT to study its
potential as a site for vaccination against immunodeficiency
viruses. We will show that tonsillar vaccination with
SIVmac239nef (15) protects against wild-type SIVmac251,
much like the protection reported when vaccine is given i.v.
Surprisingly, vaccinated animals rapidly and efficiently contain
the challenge SIVmac251 at the tonsil portal of entry, even
though the vaccine strain continues to replicate. In tissue
sections, protection is accompanied by an expansion of mature
DCs and  T cells but not by an expansion of cytotoxic cells that
express perforin or granzyme B. We suggest that exposure to
immunodeficiency viruses in the setting of vaccination allows
DCs and  T cells, possibly by a release of  chemokines, to
exert innate functions that resist challenge with infectious
viruses.
Materials and Methods
Animals. Juvenile rhesus macaques (Macaca mulatta) of Indian
origin were bred at the German Primate Center or imported
from the Laboratory Animal Breeder & Services (Yemassee,
NC) or China. Animal care and handling (16) was performed
according to in-house guidelines and German Animal Protec-
tion Laws. Monkeys were of either sex, weighed 3.1–4.8 kg, and
tested negative for antibodies to simian T lymphotrophic virus
type 1, simian D-type retrovirus, and SIV. Viral inoculation,
physical exams, and bleeding used ketamine anesthesia,
whereas lymph node removal used combined ketamine, xyla-
zine, and atropine.
Vaccination with Attenuated nef-Deleted SIV and Challenge with
Pathogenic Wild-Type SIV. For vaccination, we used an SIVnef
virus stock (15) attenuated by a 513-bp deletion in nef and the
U3 region (SIVNU) (17). We injected 300 median tissue
culture 50% infective dose (TCID50) i.v. into three animals and
applied 105 TCID50 to palatine and lingual tonsils of 13
monkeys as described (14). To monitor long-term protection,
five vaccinees (three immunized i.v and two by the tonsillar
route 26 weeks before) were challenged, along with two
untreated controls through the tonsils with 2–3  103 TCID50
of SIVmac251 provided by A. M. Aubertin (Institute of
Virology, Medical Faculty, Strasbourg, France; ref. 14). Some
vaccinees were observed for 56–57 weeks after challenge and
are still alive. To monitor short-term protection at the portal
Abbreviations: DC, dendritic cell; SIV, simian immunodeficiency virus; MALT, mucosa-
associated lymphoid tissue; TCID50, tissue culture 50% infective dose; PBMC, peripheral
blood mononuclear cell.
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of virus challenge, the other 10 SIVnef vaccinees were
challenged at 26–27 weeks through the tonsils along, with 10
untreated controls. The challenge was 2–3  103 TCID50 of
SIVmac251 but represented a further in vitro passage from A.
M. Aubertin’s virus stock in rhesus monkey peripheral blood
mononuclear cells (PBMCs) (kindly provided by S. Norley,
Robert-Koch-Institute, Berlin).
Assays for Infection. Cell-associated viral loads were determined
in a limiting dilution coculture assay (14, 16), and RNA loads by
quantitative competitive PCR (18).
Quantitative Real-Time RT-PCR. As described (19), virus RNA
(virus RNA isolation kit, Qiagen, Valencia, CA) in 10 l per
reaction was amplified by a one-tube real-time RT-PCR using
a brilliant single-step QRT-PCR core kit (Stratagene). PCRs
were run in a 40-l reaction in duplicate with 4 l of 10 core
buffer, 5 mM MgCl20.8 mM dNTP mix200 nM primers150
nM fluorogenic TaqMan probe1.25 units of Stratascript
RT0.025 units of TaqDNA-polymerase. To quantify viral
loads, standard RNA templates were created from the
p239Sp5 plasmid (donated by R. M. Ruprecht, Dana–Farber
Cancer Institute, Boston; ref. 19), with a detection limit of 25
viral copies per ml of plasma.
In Situ Hybridization. Virus replication in frozen and paraffin
sections was detected with a 35S-antisense probe (Lofstrand
Laboratories, Gaithersburg, MD; ref. 20), and the number of
infected cells was recorded per mm2. To discriminate between
cells producing vaccine and wild-type virus, we labeled sections
with nef antibodies before in situ hybridization.
Characterization of Isolates by PCR. C8166 cells infected with
isolates recovered from the lymphoid organs or PBMCs were
lysed in buffer K (50 mM KCl15 mM TrisHCl, pH 7.52.5 mM
MgCl20.5% Tween 20100 g of proteinase K per ml) for 0.5 h
overnight before heat inactivation at 95 C for 10 min. The lysates
were PCR-amplified with two different primer pairs, allowing us
to differentiate between SIVnef virus and nef-containing chal-
lenge virus. By using the primers Sns and Sna (21), which flank
the deletion in nef and the U3 region of SIVnef, a 163-bp
fragment and a 672-bp fragment were obtained in the PCR for
SIVnef and SIVmac251, respectively. To detect SIVmac251
but not SIVnef, the PCR was performed with the Sns primer
and the primer na (21), which is complementary to the U3
region deleted in SIVnef, resulting in a 556-bp PCR product in
the case of SIVmac251. Isolates were classified as vaccine virus
(V) if the SnsSnaPCR resulted in a 163-bp fragment, as
challenge virus (C) if the Snsna PCR resulted in a 556-bp
fragment, and as vaccine and challenge virus (VC) if both
PCRs gave a product of the expected size. The PCR conditions
were: 94°C for 2 min, 40 cycles of 40 sec at 94°C, 1 min at 61°C,
and 1 min at 72°C.
Immunohistochemistry. Paraffin and frozen sections (fixed in 4%
paraformaldehyde for 10 min) of tonsils were analyzed. Dewaxed
paraffin sections were subjected to high-temperature antigen
retrieval. Sections were incubated with antibodies to CD4 (NCL-
CD4-1F6; Novocastra, Newcastle upon Tyne, U.K.), CD8 (C8
144B; Dakopatts, Hamburg, Germany), perforin (P1–8; Kamiya
Biomedical Company, Seattle), granzyme B (GrB-7; Dakopatts),
CD1a (Leu 6; BD Pharmingen, San Diego), Langerin (22),
DC-LAMP (23), CD83 (HB15A; Immunotech, Marseille,
France), anti-nef (ARP3092; Centralized Facility for AIDS
Reagents, National Institute for Biological Standards and Con-
trol, Potters Bar, U.K.), and  T cells (B1.1; BD Pharmingen).
Antibody binding was visualized with the alkaline-phosphatase
anti-alkaline phosphatase method with New Fuchsin as a
chromogen.
Statistical Analysis. Differences between control and vaccine
values were analyzed by SPSS 9.0.1 or the GRAPHPAD PRISM
software, and P values 0.05 in the unpaired Student’s t test or
Mann–Whitney U test for continuous variables, were scored as
significant.
Results
Long-Term Protection with SIVnef Vaccination by Tonsillar and i.v.
Routes. SIVnef (from SIVmac239) was applied to the tonsils
(15) to compare its long-term protection with i.v. vaccination
(24). Three animals were infected i.v. with 300 TCID50 SIVnef,
three others received 105 TCID50 SIVnef applied atraumati-
Fig. 1. Long-term protection after SIVnef vaccination. (a) Study design whereby monkeys were vaccinated through the tonsils or i.v., challenged with
SIVmac251 through the tonsil, and studied for 56 weeks. (b) Plasma viral RNA before and after challenge with SIVmac251. Animal 1961 was not challenged due
to high viral load.
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cally to the tonsils, and two animals served as unvaccinated
controls (Fig. 1a). Twenty-six weeks later, all were challenged at
the tonsil with 2–3  103 TCID50 SIVmac251. Cell-associated
viral loads were assessed in limiting dilution assays (Fig. 6, which
is published as supporting information on the PNAS web site)
and plasma viral RNA measured (Fig. 1b). Following challenge,
there was little or no increase in prevaccination viral loads of
102 infectious units per106 PBMC and 101 to 104 RNA
equivalents in all five vaccinees (Figs. 1b and 6). In contrast, both
controls reached levels of 103 infectious units per 106 PBMC
and 106 RNA copies per ml (Fig. 1b) Therefore, vaccination
with SIVmac239nef, by either i.v. or tonsillar routes, pro-
vides long-term protection against mucosal challenge with
SIVmac251.
Fig. 2. Early protection of monkeys after SIVnef tonsillar vaccination. (a) Study design with 10 monkeys vaccinated through the tonsil and 10 controls.
At 26 weeks, all were challenged with SIVmac251 through the tonsil (gray arrow). Four animals from each group were killed at days 4 and 1415, and two
per group at 7– 8 days after challenge (blue arrows), to look for protection at the entry portal. (b) Plasma RNA of vaccinated and control animals before
and after challenge.
Table 1. Cell-associated viral load and detection of vaccine and challenge forms of SIV by PCR 4 days
after challenge
Tissue examined
SIVnef-vaccinated monkeys Control nonvaccinated monkeys
10121 11106 11111 10118 10659 10662 10655 10656
PBMC 0.33(V) — 8(nd) 2(V) 2(C) 1(C) 0.33 2
Palatine tonsil 2(V) — 8(V) 32(V) 8 32 32(C) 64(C)
Spleen 0.33(V) — 32(V) 64(V) 4(C) 4 2 0.33
LN axillary 4(V) 0.33(V) 32(V) 32(V) — 28 2 0.33
LN mesenteric 0.33(V) — 2(V) 0.33(nd) 0.33 — 2 —
LN submandibular 0.33(V) — 4(V) 64(V) 4 2(C) 1 —
LN retropharyngeal 0.33(V) 1(VC) 4(V) 16(V) 16 16 2 1
Thymus — — — — — — — —
Cell-associated viral load expressed as infectious units per 106 mononuclear cells. Characterization of reisolates by PCR are shown in
parentheses. —, virus isolation negative; V, vaccine virus; C, challenge virus; nd, not done. In the control animals, we performed PCR on
only one to two reisolates per monkey, as indicated, to verify the presence of wild-type challenge virus.









Protection by Tonsillar SIVnef Is Manifest in the Blood Early After
Challenge. To study early events at the virus entry portal, we
vaccinated 10 monkeys 26 weeks earlier with 105 TCID50
SIVnef on the tonsils and challenged these animals and 10
unvaccinated controls with 2–3  103 TCID50 SIVmac251
through the tonsil (Fig. 2a). We then studied four animals from
each group at days 4 and 1415, and two at days 78. With the
exception of monkey 10140, the mean viremia of the vaccinated
animals was 770  250 RNA equivalents per ml at weed 26
before challenge, and after challenge, the mean viremia for all
three time points (day 4, 1 week, and 2 weeks) was 590  230 per
ml (Fig. 2b). For the controls, the mean viremia after challenge
rose to 2.3  105  0.2  105 RNA equivalents per ml for two
monkeys at days 78 and 2.1  106  1.2  106 for four animals
at days 1415 (P  0.0001 relative to vaccinated challenged
monkeys). Similarly, the vaccinated animals showed little or no
boost in infectious units in PBMC (Fig. 7, which is published as
supporting information on the PNAS web site). Therefore, all
vaccinees were protected at early times against the challenge
virus.
Protection by Tonsillar SIVnef Is Manifest in Lymphoid Tissues Early
After Challenge. We monitored SIV in individual lymphoid
organs in all animals with two assays. First, we measured
infectious units in cell suspensions cocultured with a permissive
cell line. In the controls, infectious virus became detectable at
day 4 in the tonsil and draining retropharyngeal node and rose
to 103 infectious units per 106 cells in most lymphoid organs by
days 78 and 1415. In contrast, infectious virus remained at
10–100 infectious units per 106 cells in vaccinated and chal-
lenged monkeys, except for 10140 (Tables 1–3). Virus isolates
were characterized by PCR to distinguish the challenge nef-
containing virus from the vaccine strain (Materials and Methods).
In the controls, the challenge virus was already detected by PCR
at day 4 in the tonsil, but in 5 of 6 vaccinees, only the SIVnef
vaccine and not the challenge virus was observed at 1 week after
challenge (Tables 1–3). Second, we looked for productively
infected cells by in situ hybridization of sections with 35S anti-
sense SIV RNA and by immunolabeling for nef protein. The
early protection against challenge virus was clearly evident by
both approaches (Fig. 3). RNA cells were rare in the tonsils of
vaccinees challenged with wild-type SIV, in contrast to abundant
infected cells in controls (Fig. 3 a vs. b). The nef protein was also
readily identified in cells of the controls but not the vaccinees;
Fig. 3. Early protection against SIV challenge at the tonsillar entry portal. (a
and b) In situ with 35S-antisense SIV RNA in sections of the lingual tonsil, 7 days
after challenge of unvaccinated (a) and SIVnef-vaccinated (b) animals. Each
black deposit is an infected cell. (c and d) Wild-type SIVmac251 was detected
in infected cells (black) by immunolabeling (red) for viral nef protein in the
unvaccinated controls (c) but not SIVnef vaccinees (d; arrow to a nef	-
infected cell).
Table 2. Cell-associated viral load and detection of vaccine and






10124 10130 10674 10678
PBMC 1(V) — 256 256
Palatine tonsil 4(VC) 4(V) 4,096(C) 4,096(C)
Spleen 16(V) 64(V) 4,096 1,024
LN axillary 32(V) 32(V) 128 1024
LN mesenteric 8(V) 8(V) 4096 256
LN submandibular 8(V) 128(V) 1,024 1,024
LN retropharyngeal 2(C) 16(V) 4,096 1,024
Thymus — 1(V) 128 2
Cell-associated viral load expressed as infectious units per 106 mononuclear
cells. Characterization of reisolates by PCR are shown in parentheses. —, virus
isolation negative; V, vaccine virus; C, challenge virus; nd, not done. In the
control animals, we performed PCR on only one to two reisolates per monkey,
as indicated, to verify the presence of wild type challenge virus.
Table 3. Cell-associated viral load and detection of vaccine and challenge forms of SIV by PCR 14–15 days
after challenge
SIVnef-vaccinated monkeys Control nonvaccinated monkeys
10138 10140 11112 11118 10685 10686 10931 10932
PBMC C 64(nd) — 2(C) 8,192 512 128(C) 128(C)
Palatine tonsil 16(V) 4,096(VC) 32(VC) 32(VC) 8,192(C) 4,096(C) 512 32
Spleen 0.33(V) 4,096(V) 8(V) 4(V) 8,192 8,192 2,048(C) 256
LN axillary 4(VC) 512(VC) 8(V) 8(V) 4,096 8,192 8192 1,024
LN mesenteric — 1,024(VC) — 4(C) 4,096 8,192 4096 8,192
LN submandibular 4(V) 1,024(VC) 4(V) 32(VC) 1,024 8,192 256 512
LN retropharyngeal 0.33(V) 1,024(VC) 4(C) 16(nd) 4,096 8,192 4096 512
Thymus — 0.33(VC) — 0.33(C) NA 64 1,024 1,024
Cell-associated viral load expressed as infectious units per 106 mononuclear cells. Characterization of reisolates by PCR are shown in
parentheses. —, virus isolation negative; V, vaccine virus; C, challenge virus; nd, not done; NA, reisolate not available due to bacterial
contamination. In the control animals, we performed PCR on only one to two reisolates per monkey, as indicated, to verify the presence
of wild-type challenge virus.
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when double labeling was carried out (Fig. 3c), most RNA cells
in the control monkeys were also nef. Together, the results in
Tables 1–3 and Fig. 3 indicate that challenge virus rapidly took
hold in control monkeys and spread vigorously in a systemic
manner. In contrast, vaccinated monkeys quickly and efficiently
resisted the same challenge at the tonsillar portal of SIV entry.
Initial Studies of Protection Mechanisms at the Portal of SIV Entry. We
assessed three changes:
(i) SIV challenge does not expand cells with cytotoxic gran-
ules: To identify potential killer cells (CD8 cytolytic T lym-
phocytes and natural killer cells), we stained tonsil sections for
perforin and granzyme B. In the controls, killer cells expanded
1 week after challenge (Fig. 4a), similar to prior work during
exposure to SIVnef vaccine; these included both CD8 T cells
and CD3	 natural killer cells (15). In contrast, when vaccinated
animals were challenged (Fig. 4b), granzyme B cells increased
a little and perforin cells not at all. Within the limits of assay
sensitivity, this implies that killer cells did not expand during the
time SIV challenge was being resisted at the portal of entry.
(ii) Increased  T-cells in the tonsils from vaccinees:  T
cells have innate roles (25). Recent studies showed that HIV and
SIV immunization expanded these cells, which can produce
-chemokines and IFN- (26, 27). We found that control tonsils
contained only few  T cells (1.3  0.6 cells per mm2), mainly
in crypt epithelium and T-dependent zones. In contrast, there
was 5-fold elevation (6.5 2.6  T cells per field; P  0.0001)
in vaccinated animals before and after SIV challenge (Fig. 4c).
Unvaccinated animals, possibly because of greater viral loads,
showed even larger increases in  T cells after challenge (mean
19.3  1.5 cells per field for all three time points examined; Fig.
4c). Therefore, both infection and vaccination expands  T cells
at the entry portal.
(iii) Mature but not immature DCs expand in the tonsils of
vaccinated macaques. We also observed an increase in mature
DCs in the tonsils of vaccinees. In the case of the DC-LAMP
marker (23), increases were seen from 16  1.2 in controls to
22  2.0 in vaccinated animals (P 
 0.02), whereas in the case
of CD83, DCs increased from 12  2.0 in controls to 22  1.5
for all vaccinated challenged animals (P  0.0001; Fig. 5 a and
b). In contrast, immature DCs, (CD1a or Langerin; ref. 22),
did not increase (Fig. 5c). Therefore, a distinct feature of the
portal of entry in vaccinees is an expansion of mature DCs.
Discussion
Here, we evaluated a tonsillar mode of attenuated SIVnef
vaccination. Virus was applied to palatine and lingual tonsils
with a cotton swab. Some virus might have spilled over to other
parts of the oral cavity and gastrointestinal tract, but spillage
might not be large, given a lack of infection with either SIV or
SIVnef in gastric lymph nodes (14, 15). We chose the tonsil
route for two reasons. First, this could be valuable for vaccina-
tion, as in the lingual application of attenuated Sabin polio
vaccine; second, this route facilitated the study of early events at
a MALT site of entry. Comparison of set point viral load levels
in monkeys infected with the same SIVnef virus by the tonsillar
route (n 
 16; this study and ref. 15) or i.v. (n 
 7; this study and
ref. 17) did not show reduced pathogenicity of tonsillar infection,
also in relation to other studies with nef-deletion mutants of SIV
(24, 28, 29). We found that tonsil vaccinees were protected
against a tonsillar challenge with pathogenic SIVmac251. A
distinct feature was the early protection provided by vaccination
at the site of virus entry.
Once long-term protection was observed in vaccinated mon-
keys, we considered some mechanistic aspects at the entry
portal. Importantly, the challenge virus was resisted at the same
time that vaccine virus retained its infectivity in the oral MALT
and distal lymphoid organs. Possibly, protection was due to
neutralizing antibodies. Passive transfer of neutralizing antibody
before infection can provide protection at a mucosal surface
Fig. 4. Lack of expansion of perforin killer cells in vaccinated animals
challenged with wild-type SIVmac251. Cytotoxic cells were identified by im-
munolabeling (red) for perforin 2 weeks after challenge with SIV in unvacci-
nated (a) and SIVnef-vaccinated (b) monkeys. The results at different time
points after challenge are shown in c.  cells were also enumerated, and
means of each group are shown (P  0.0001 for the differences in  cells
between controls and SIVnef-vaccinated animals, and between controls and
SIV-challenged animals).
Fig. 5. Expansion of DC-LAMP DCs in vaccinees challenged with SIVmac251.
(a and b) DCs immunolabeled (red) for the mature DC marker, DC-LAMP, in
palatine tonsils from unvaccinated (a) and SIVnef-vaccinated (b) monkeys. (c)
Quantitative data and means from each group (P 
 0.01 for DC-LAMP; P 

0.001 for CD83).









(30), but if such antibodies were present in the vaccinees, how
would they account for resistance to a high dose of challenge
virus but allow for replication of vaccine virus? Possibly, killer
lymphocytes were fully active and able to kill cells infected with
challenge virus (31). CD8 T cells lytic for SIV-infected targets
help to control virus replication during primary infection (32).
However, we did not see a rapid expansion of perforin killer
cells after challenge, as assessed by immunolabeling of sections.
This finding is in agreement with recent data showing that live
attenuated SIV does not yield a vigorous T cell response during
protection to virus challenge (33).
In contrast,  T cells may have been provided some protec-
tion. SIVnef tonsillar vaccination elevated  T cells, which
may be important in vaccine immunity (26, 27); e.g., ex vivo-
depletion of  T cells from PBMCs of immunized macaques
significantly decreases CD8 suppressor activity for SIV repli-
cation and the production of RANTES, MIP-1, and MIP-1
(26). Also,  T cells from individuals vaccinated with recom-
binant canary pox HIV produce IFN- (27).  T cells can
promote the maturation of cultured monocyte-derived DCs,
which present antigen better to naive T cells (34). Thus,  T cells
can contribute to innate and adaptive arms of immunity.
We also observed increases in mature DCs at the site of entry
of the challenge virus. This increase had not been studied
previously in other vaccine settings. DCs might produce cyto-
kines like IL-12 and IFNs, and chemokines like MIP-1 (CCL4),
MIP-1 (CCL5), and RANTES (CCL6). Immunization with
live-attenuated SIV vaccine leads to production of CCL 4, 5, and
6 (35), which can block viral entry (36). These chemokines are
also induced when DCs encounter a maturation stimulus, such
as CD40L (37) on immune CD4 T cells. Therefore, we would
suggest that immune T cells stimulate DCs to produce large
amounts of chemokines, in tandem with those produced by  T
cells (above), and these quickly block the take and spread of
SIVmac251. Perhaps these mechanisms also prevent superin-
fection in naturally infected individuals.
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